A Phase Ib Pharmacodynamic Study of MRX34, A Liposomal Microrna-34 Mimic, In Advanced Solid Tumours
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2016
At a glance
- Drugs MRX 34 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Pharmacodynamics
- 20 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment, as per Mirna Therapeutics media release.
- 29 Mar 2016 According to a Mirna Therapeutics media release, this trial is expected to begin in late 2016.
- 27 Aug 2014 New trial record